5 completed, 2 recruiting. 7 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Recruiting 2 |
| Phase 2 | 4 | Completed 3, Recruiting 1 |
Follow Hyperoxaluria, Primary: new trials by email Literature Review of Hyperoxaluria, Primary trials Research Report on Hyperoxaluria, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) YOLT-203 - Primary Hyperoxaluria Type 1, PH1 | Phase 1 | Recruiting | YolTech Therapeutics Co., Ltd | 9 | 2026-08-01 | 2026-08-20 |
| Phase 1/2 Study of ABO-101 in Primary Hyperoxaluria Type 1 (redePHine) ABO-101 - Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | Recruiting | Arbor Biotechnologies | 23 | 2025-06-16 | 2026-10-19 |
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients DCR-PHXC, Sterile Normal Saline (0.9% NaCl) - Primary Hyperoxaluria Type 3 | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 6 | 2020-09-14 | 2024-09-19 |
| Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria DCR-PHXC, Placebo - Primary Hyperoxaluria | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 43 | 2017-12-06 | 2024-09-19 |
| Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1 Lumasiran, Placebo - Primary Hyperoxaluria Type 1 (PH1) | Phase 1 / Phase 2 | Completed | Alnylam Pharmaceuticals | 52 | 2016-03-08 | 2020-01-30 |
| Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Oxabact OC5 capsules, Placebo capsules - Primary Hyperoxaluria | Phase 1 / Phase 2 | Completed | OxThera | 28 | 2013-12-01 | 2015-10-16 |
| Hydroxyproline Influence on Oxalate Metabolism Hydroxyproline and Leucine - Hyperoxaluria | Phase 1 / Phase 2 | Completed | Mayo Clinic | 22 | 2013-09-01 | 2017-07-02 |
Hyperoxaluria (3) · Primary hyperoxaluria type 1 (3) · Kidney Calculi (1)
Carbohydrate Metabolism, Inborn Errors (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Genetic Diseases, Inborn (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Metabolic Diseases (7) · Metabolism, Inborn Errors (7) · Nutritional and Metabolic Diseases (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Hyperoxaluria (4) · Calculi (1) · Nephrolithiasis (1)
Hydroxyproline (1) · Leucine (1) · lumasiran (1) · nedosiran (1)
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (2) · Alnylam Pharmaceuticals (1) · Arbor Biotechnologies (1) · Mayo Clinic (1) · OxThera (1) · YolTech Therapeutics Co., Ltd (1)
Germany (5) · United Kingdom (5) · France (4) · United States (4) · Netherlands (3) · China (1) · Israel (1) · Tunisia (1)
Alexandra Haagensen, MD, MBA (1) · Bernd Hoppe, MD PhD (1) · Daniel Ory, MD (1) · John C Lieske, MD (1) · Tracy McGregor, MD, MSCI (1)
PMID 33985991, PMID 40601241, PMID 41388232
2015 (1), U54DK083908 (1)